Private company

Turning Point Therapeutics, Inc.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2022 annual report the company says: “We are a clinical-stage precision oncology biopharmaceutical company designing and developing novel therapies that target genetic drivers of cancer to improve the lives of patients. We have developed a macrocycle platform from which we designed our current pipeline of proprietary small, compact tyrosine kinase inhibitors (TKIs) with rigid structures that have the potential to bind to their targets with greater precision and affinity than other kinase inhibitors.”49 It is headquartered in San Diego, California.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Diego, California1
  • Incorporated inDE2
  • Business address10628 Science Center Drive, Suite 200, San Diego, Ca 921212
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-772.0%Operating margin3
-767.3%Net margin3
23.3%Revenue growth, 20213
-24.8%Return on equity3
-$156.3MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Research and development100¢$193.0M

Out of $30.8M in revenue.3 The company lost money this year.

Financial statements

Revenue3$30.8M in 2021+23% since 2020
0$10.0M$20.0M$30.0M$40.0M2020: $25.0M$25.0M20202021: $30.8M$30.8M2021+23%
Operating income453-$238.0M in 2021+1323% since 2017
-$300.0M-$200.0M-$100.0M02017: -$16.7M-$16.7M20172018: -$25.6M-$25.6M2018+53%2019: -$77.7M-$77.7M2019+203%2020: -$161.8M-$161.8M2020+108%2021: -$238.0M-$238.0M2021+47%
Net income453-$236.6M in 2021+1326% since 2017
-$300.0M-$200.0M-$100.0M02017: -$16.6M-$16.6M20172018: -$24.8M-$24.8M2018+49%2019: -$72.1M-$72.1M2019+191%2020: -$157.3M-$157.3M2020+118%2021: -$236.6M-$236.6M2021+50%
Fiscal year201620172018201920202021
Revenue$25.0M3$30.8M3
Research and development$15.2M4$21.1M5$57.9M3$113.4M3$193.0M3
Operating expenses$268.8M3
Operating income-$16.7M4-$25.6M5-$77.7M3-$161.8M3-$238.0M3
Income tax$05$03$03$03
Net income-$16.6M4-$24.8M5-$72.1M3-$157.3M3-$236.6M3

Compare Turning Point Therapeutics, Inc. with another company

Corporate structure

Turning Point Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Turning Point Therapeutics, Inc.

  • Cormorant Asset Management, LP Filed SC 13G on Turning Point Therapeutics, Inc., latest Feb 14, 2022
  • PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G/A on Turning Point Therapeutics, Inc., latest Feb 14, 2022
  • VANGUARD GROUP INC Filed SC 13G/A on Turning Point Therapeutics, Inc., latest Feb 10, 2022
  • FMR LLC Filed SC 13G/A on Turning Point Therapeutics, Inc., latest Feb 9, 2022
  • Wellington Management Company Filed SC 13G on Turning Point Therapeutics, Inc., latest Feb 4, 2022
  • Turning Point Therapeutics, Inc. San Diego, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Turning Point Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$6.5M3 Dec 31, 2021$4.0M3 Dec 31, 2020+59.9%
Accumulated depreciation$2.7M3 Dec 31, 2021$1.4M3 Dec 31, 2020+83.6%
Property and equipment, net$3.8M3 Dec 31, 2021$2.6M3 Dec 31, 2020+46.8%
Operating-lease assets (leased space)$5.2M3 Dec 31, 2021$3.4M3 Dec 31, 2020+53.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$427.9M3 Dec 31, 2021$554.1M3 Dec 31, 2020−22.8%
Marketable securities, current$553.7M3 Dec 31, 2021$568.4M3 Dec 31, 2020−2.6%
Debt securities available for sale$553.7M3 Dec 31, 2021$568.4M3 Dec 31, 2020−2.6%

Leadership

Who has led Turning Point Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Athena Countouriotis2019–2022

President

  1. Athena Countouriotis2019–2022

Chief financial officer

  1. Yi Larson2019–2021
  2. Paolo Tombesi2021–2022
20202025
Board members and other officers (21)

Former names

  • TP Therapeutics, Inc.Oct 30, 2018 to Oct 30, 20182
  • TP Therapeutics, INCJan 6, 2014 to May 25, 20172

Timeline

  1. Aug 17, 20228-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer30
  2. Aug 8, 20228-K Results of operations31
  3. Jun 24, 20228-K Entered a material agreement32
  4. Jun 21, 20228-K Shareholder vote33
  5. Jun 3, 20228-K Other events34
  6. Jun 3, 20228-K Entered a material agreement; Executive or director change35
  7. May 10, 20228-K Results of operations; Other events36
  8. May 5, 20228-K Entered a material agreement37
  9. Apr 13, 20228-K Other events38
  10. Mar 4, 20228-K Executive or director change39
  11. Feb 28, 20228-K Results of operations40
  12. Feb 18, 20228-K Executive or director change41
  13. Apr 16, 2019New chief executive Athena Countouriotis becomes CEO8

Calendar

When it reported results

  1. Aug 8, 2022Reported quarterly or annual results31
  2. May 10, 2022Reported quarterly or annual results36
  3. Feb 28, 2022Reported quarterly or annual results40
  4. Jan 18, 2022Reported quarterly or annual results42
  5. Nov 9, 2021Reported quarterly or annual results43

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

65 filings to the SEC since October 2021: 1 annual reports, 3 quarterly reports, 17 major events, 22 insider forms, 5 large holders, 17 other. The latest 20:

  1. Aug 29, 202215-12G EDGAR
  2. Aug 22, 2022EFFECT EDGAR
  3. Aug 17, 20224 FORM 4 SUBMISSION EDGAR
  4. Aug 17, 20224 FORM 4 SUBMISSION EDGAR
  5. Aug 17, 20224 FORM 4 SUBMISSION EDGAR
  6. Aug 17, 20224 FORM 4 SUBMISSION EDGAR
  7. Aug 17, 20224 FORM 4 SUBMISSION EDGAR
  8. Aug 17, 20224 FORM 4 SUBMISSION EDGAR
  9. Aug 17, 20224 FORM 4 SUBMISSION EDGAR
  10. Aug 17, 20224 FORM 4 SUBMISSION EDGAR
  11. Aug 17, 20224 FORM 4 SUBMISSION EDGAR
  12. Aug 17, 20224 FORM 4 SUBMISSION EDGAR
  13. Aug 17, 20224 FORM 4 SUBMISSION EDGAR
  14. Aug 17, 2022S-8 POS EDGAR
  15. Aug 17, 2022S-8 POS EDGAR
  16. Aug 17, 2022S-8 POS EDGAR
  17. Aug 17, 2022S-8 POS EDGAR
  18. Aug 17, 2022POS AM EDGAR
  19. Aug 17, 20228-K EDGAR
  20. Aug 16, 2022SC 14D9/A EDGAR

The 65 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 0 buys and 6 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 27, 2022TOMBESI PAOLOEVP & Chief Financial OfficerSale1,183$74.94$88.7KForm 4
Feb 9, 2022Reich SiegfriedEVP & Chief Scientific OfficerSale397$36.30$14.4KForm 4
Feb 9, 2022Partridge Andrew JohnEVP & Chief Commercial OfficerSale221$36.30$8.0KForm 4
Feb 9, 2022North AnnetteEVP & General CounselSale669$36.30$24.3KForm 4
Feb 9, 2022Hirmand MohammadEVP and Chief Medical OfficerSale669$36.30$24.3KForm 4
Feb 9, 2022Countouriotis AthenaPresident & CEOSale2,971$36.30$107.8KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Turning Point Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTurning Point Therapeutics, Inc.1
  • CIK0001595893
  • Employer ID (EIN)46-38261661
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address10628 Science Center Drive, Suite 200, San Diego, CA 921211
  • Phone858-926-52511
  • Shares outstanding50,074,277 as of Aug 1, 20227
  • Public float$3.7B as of Jun 30, 20213
  • On EDGAR sinceJan 6, 20141
  • Filings302 in all: 4 (108), 8-K (60), 3 (26), SC 13G/A (12), 10-Q (11), SC 13G (9), CORRESP (8), 424B5 (5)1
    All 36 form types

    DEFA14A (4), S-8 (4), S-8 POS (4), SC 13D/A (4), SC 14D9/A (4), SC TO-T/A (4), 10-K (3), D (3), DEF 14A (3), EFFECT (3), S-1/A (3), UPLOAD (3), 424B4 (2), DRS (2), S-1 (2), SC 13D (2), SC14D9C (2), 15-12G (1), 25-NSE (1), 8-A12B (1), CERT (1), FWP (1), POS AM (1), S-1MEF (1), S-3ASR (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Feb 28, 2022
    Quarterly report (10-Q) Aug 8, 2022
    Proxy statement (DEF 14A) Apr 29, 2022
    Latest 8-K (8-K) Aug 17, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
  37. 37
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49